Peng Shiyong, Li Wenqiang, Lv Luxian, Zhang Zhongjiang, Zhan Xiping
Institute of Psychiatry and Neuroscience, Xinxiang Medical University, Xinxiang, Henan 435000, China.
Henan Key Lab of Biological Psychiatry, the Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 435001, China.
Discov Med. 2018 Oct;26(143):127-136.
Schizophrenia and major depression disorders, both being of pathological synaptogenesis, are the most common psychiatric disorders worldwide. These diseases, if not treated effectively, may cause suicide and are a serious social and economic challenge. Although schizophrenia and depression can be significantly improved with the second-generation atypical antipsychotics, rising drug resistance has limited their efficacy. Repetitive Transcranial Magnetic Stimulation (rTMS) has appeared to be a promising therapy against severe mental disorders, but it is still controversial primarily due to inadequate evaluation. It is essential to have a reliable biological marker to evaluate and diagnose schizophrenia or depression. Brain-derived neurotrophic factor (BDNF) has appeared to play a critical role in certain neurobiological modifications that may otherwise lead to schizophrenia or depression. Meta-analyses have demonstrated that serum BDNF levels were tightly correlated with the courses of severe schizophrenia and major depression disorders. This article presents a review of BDNF as a neurobiological marker for schizophrenia and depression and for the efficacy of rTMS treatments of these mental diseases.
精神分裂症和重度抑郁症均存在病理性突触形成，是全球最常见的精神疾病。这些疾病若未得到有效治疗，可能导致自杀，构成严峻的社会和经济挑战。尽管第二代非典型抗精神病药物可显著改善精神分裂症和抑郁症，但耐药性的增加限制了其疗效。重复经颅磁刺激（rTMS）似乎是一种针对严重精神障碍的有前景的治疗方法，但主要由于评估不足，其仍存在争议。拥有可靠的生物标志物对于评估和诊断精神分裂症或抑郁症至关重要。脑源性神经营养因子（BDNF）似乎在某些可能导致精神分裂症或抑郁症的神经生物学改变中起关键作用。荟萃分析表明，血清BDNF水平与重度精神分裂症和重度抑郁症的病程密切相关。本文综述了BDNF作为精神分裂症和抑郁症的神经生物学标志物以及rTMS治疗这些精神疾病疗效的相关情况。
